# Wall Street's Wildest Stock Surprises Revealed!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-10-23T18:22:01.399Z
Source: https://newsyai.com/edition/8b8538e7-1cb8-4901-8bd4-e38fb7298066
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Wall Street's Fresh Holy Trinity of "WTF Is This Stock Smoking?" – October 23, 2026 Edition**[[1]](https://tapeboard.com/most-shorted-stocks)[[2]](https://www.chartmill.com/stock/markets/usa/screener/most-shorted-stocks)

Back at it, you beautiful degenerates. Markets remain the same glorious shitshow—AI hype juicing the Nasdaq while the Dow sits on its ass like a retiree in Boca, and crude oil bounces around like a drunk on a pogo stick. I scoured the freshest short-interest scans (recent settlement data with live borrow fees and volatility overlays) for three *brand-new* names where the bears are piled higher than a Wall Street bonus pool on a bad year, and the bulls are yelling “squeeze me harder.” No repeats of the usual suspects like SOUN, METC, BTBT, ONDS, BBAI, EOSE, CLSK, or LCID. Just pure, unfiltered fresh meat with serious short pressure and “prove me wrong, bitch” vibes. Here’s today’s unholy trinity.

### 1. WULF (TeraWulf): The Bitcoin Miner That’s Either Building the Next AI Data Center Empire or Just Hashing Its Way to Dilution Hell
**The Bull Case (Pivot to Stable HPC/AI Leasing with Massive Contracted Revenue That Could Crush Shorts):**  
Bulls are creaming over WULF’s shift from volatile crypto mining to long-term, credit-backed AI/HPC data center leases—think Google-backed deals at Lake Mariner and a $19B+ Anthropic lease at the Kentucky site starting late 2027. Expanding capacity, potential for more big-tech tenants, and any lease ramp or production beats could spark a short squeeze (short interest ~31% of float in recent reads, with elevated borrow fees and volatility screaming opportunity). “We’ve got the power and the contracts—watch the MW flow and shorts get WULF-ed” is the battle cry. AI tailwinds? Margin inflection from stable revenue? Shorts left hashing regrets.[[3]](https://marketcatalyst.ai/posts/terawulf-s-ceo-says-it-is-an-energy-infrastructure-company-not-a-neocloud-as-morgan-stanley-calls-the-stock-s-october-slide-mispriced)[[4]](https://www.dombey.capital/market/why-terawulf-stock-fell)

**The Bear Case (High-Vol Crypto-to-AI Spec Drowning in Debt, Dilution, and Execution Risks):**  
Reality check: Ongoing losses, cash burn during the transition, aggressive capex needing fresh debt/equity (dilution city), Bitcoin price swings still matter for legacy ops, intense competition in data centers, and questions about timely lease ramp and financing costs amid higher rates. High shorts reflect the market’s “yeah, right” on hitting those multi-billion contracted revenues without blowing up the balance sheet. One missed lease, funding crunch, or macro hiccup and it’s dilution or worse. TeraWulf? More like “tera-wiped—shorts are mining the downside.”[[5]](https://www.financecharts.com/stocks/WULF/bulls-bears)[[6]](https://www.marketbeat.com/instant-alerts/price-terawulf-nasdaq-wulf-stock-falls-12-heres-why-2026-10-22/)

**My First-Principles Breakdown:**  
Strip it down: Success in this game wins on cheap/reliable power access, sticky long-term contracts with creditworthy tenants, capital discipline, and scaling without excessive dilution—not just shiny rigs or hype leases. WULF has real infrastructure momentum and big-name deals in the pipeline, but “dominance” requires surviving funding cycles, proving the pivot economics beat pure miners or hyperscalers, and navigating a brutal competitive/interest-rate landscape. Shorts correctly flag the execution and leverage risks; bulls correctly flag the asymmetric upside if AI demand explodes and leases deliver. High-vol energy/AI bet—entertaining as hell, size accordingly or cry into your empty hash rate later.

### 2. NVAX (Novavax): The Vaccine Player That’s Either Cashing in on Partnerships and Royalties or Just Another Biotech Burning Through Its Last Shot
**The Bull Case (Lean Partnership Model with High-Margin Royalties and Milestones That Could Trigger a Squeeze):**  
Bulls drool over NVAX’s shift to an asset-light licensing/royalty model—Sanofi deals, Matrix-M adjuvant upside, Pfizer/Takeda nods, and potential milestones/royalties flowing without the old commercial overhead. Any major partner wins, regulatory nods, or revenue beats could spark a short squeeze (short interest ~29-32% in recent scans, with volatility and borrow fees adding fuel). “We’ve got the platform and the big-pharma love—watch the royalties flow and shorts get NVAX-inated” is the mantra. Pipeline momentum? Margin inflection? Shorts left coughing up the downside.[[7]](https://seekingalpha.com/article/4876378-novavax-bear-case-broken-but-bull-case-needs-more-proof)[[8]](https://businessquant.com/stocks/nvax/)

**The Bear Case (Declining Revenue, Partner Dependency, and Pipeline Uncertainty in a Crowded Space):**  
Reality bites: Revenue spiraling down (core product sales hammered post-pandemic), heavy reliance on partners like Sanofi for timing and success (delays already noted), ongoing cash burn or thin profitability, competition from mRNA giants, and valuation assuming flawless execution on royalties/milestones. High shorts reflect the market’s “yeah, right” on sustainable growth beyond one-time payments. One partner stumble, regulatory snag, or demand slump and it’s dilution or worse. Novavax? More like “no-vax the value—shorts are vaccinating the downside.”[[9]](https://seekingalpha.com/article/4952757-novavax-stock-vaccine-maker-sees-momentum-2026-but-growth-story-holds-fundamental-risks)[[10]](https://finance.yahoo.com/markets/stocks/articles/3-reasons-nvax-risky-1-165350914.html)

**My First-Principles Breakdown:**  
Fundamentally, vaccine/tech wins on differentiated platform (recombinant + adjuvant here), partner validation, scalable royalties without capex bloat, and durable IP—not just past COVID wins. NVAX has de-risked via big-pharma deals and a leaner model, but “breakout” requires surviving partner execution risks, proving recurring revenue beyond milestones, and competing in a fast-evolving landscape without burning runway. Shorts correctly price in the dependency and decline risks; bulls correctly price in the asymmetric upside if partnerships scale. High-vol biotech bet—entertaining as hell, size accordingly or cry into your empty vial later.

### 3. ASTS (AST SpaceMobile): The Satellite Direct-to-Cell Dreamer That’s Either Connecting the World (and Printing Money) or Just Another Space Spec Getting Launch-Padded
**The Bull Case (Spectrum Moat and Carrier Partnerships Poised for Massive Scale If Launches Hit):**  
Bulls are fired up on ASTS’s unique direct-to-cell satellite tech, partnerships with major carriers, massive backlog, and spectrum value that could enable global mobile coverage. Any launch cadence wins, commercial service ramp, or deal expansions could trigger a short squeeze (short interest elevated ~20-24%+ in scans, with volatility screaming opportunity). “We’ve got the birds and the spectrum—watch the coverage flow and shorts get ASTS-tronomical” is the hype. Space tailwinds? Revenue inflection? Shorts left orbiting regrets.[[11]](https://financefeeds.com/asts-stock-price-prediction-96-bull-44-bear/)[[12]](https://www.tikr.com/blog/ast-spacemobile-has-lost-62-since-may-deutsche-bank-sees-82-upside)

**The Bear Case (Launch Delays, Cash Burn, and Starlink Competition Crushing the Vision):**  
Reality check: Pre-revenue or minimal revenue, sky-high capex and cash burn, repeated launch slips pushing timelines, intensifying competition from SpaceX/Starlink (spectrum deals and faster deployment), dilution risks via convertibles/debt, and valuation baking in flawless execution on a constellation that’s still mostly vapor. High shorts reflect the market’s “yeah, right” on hitting 45+ satellites and real subscriber revenue soon. One more delay, funding crunch, or competitor edge and it’s dilution or worse. AST SpaceMobile? More like “ASS SpaceMobile—shorts are launching the downside.”[[13]](https://www.fool.com/investing/2026/09/14/bulls-say-ast-spacemobile-is-a-10-bagger-bears-say/)[[14]](https://seekingalpha.com/article/4953475-ast-spacemobile-story-collapses-before-even-starting)

**My First-Principles Breakdown:**  
Space comms wins on spectrum rights, orbital deployment speed/reliability, carrier integration, and capital efficiency—not just cool tech demos. ASTS has carrier backing and a differentiated angle, but “success” requires surviving launch/execution cycles, proving economics vs. integrated players like Starlink, and navigating a capital-intensive race without excessive dilution. Shorts correctly flag the timeline and competition risks; bulls correctly flag the asymmetric upside if the constellation flies on schedule. High-vol space bet—entertaining as hell, size accordingly or cry into your empty orbit later.

**Bottom Line (No Crystal Ball, Just Brutal Logic):**  
These three capture the current divided vibe: AI/HPC energy pivot lottery, vaccine partnership royalty binary, and satellite constellation execution gamble. The common thread? Sky-high skepticism via shorts and volatility, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don’t), and remember: this is entertainment with numbers. Your move, degenerates.

**Sources for the terminally curious (verify this shit yourself):** Recent short-interest trackers and screens (e.g., Tapeboard, ChartMill, Exent, FindMyMoat) highlighting elevated levels in WULF, NVAX, and ASTS; analyst commentary and financial filings on sector debates. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don’t cry when it goes tits up.
